Literature DB >> 9708199

Peripheral blood stem cell transplants.

J L Byrne1, N H Russell.   

Abstract

Mesh：

Year:  1998        PMID： 9708199      PMCID： PMC500692          DOI： 10.1136/jcp.51.5.351

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN： 0021-9746            Impact factor:   3.411


× No keyword cloud information.
  29 in total

1.  Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): occurrence in an allogeneic donor of peripheral blood stem cells.

Authors:  P S Becker; M Wagle; S Matous; R S Swanson; G Pihan; P A Lowry; F M Stewart; S O Heard
Journal:  Biol Blood Marrow Transplant       Date:  1997-04       Impact factor: 5.742

2.  Molecular determination of minimal residual disease in peripheral blood stem cell harvests.

Authors:  K Langlands; J I Craig; A C Parker; R S Anthony
Journal:  Bone Marrow Transplant       Date:  1990-01       Impact factor: 5.483

3.  High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma.

Authors:  A Kessinger; J O Armitage; D M Smith; J D Landmark; P J Bierman; D D Weisenburger
Journal:  Blood       Date:  1989-09       Impact factor: 22.113

4.  Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation.

Authors:  A M Gianni; S Siena; M Bregni; C Tarella; A C Stern; A Pileri; G Bonadonna
Journal:  Lancet       Date:  1989-09-09       Impact factor: 79.321

5.  Engraftment and molecular monitoring of CD34+ peripheral-blood stem-cell transplants for follicular lymphoma: a pilot study.

Authors:  I G McQuaker; A P Haynes; S Anderson; C Stainer; R G Owen; G J Morgan; M Lumley; D Milligan; J Fletcher; E M Bessell; J M Davis; N H Russell
Journal:  J Clin Oncol       Date:  1997-06       Impact factor: 44.544

6.  Stem cell mobilization in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide.

Authors:  I G McQuaker; A P Haynes; C Stainer; S Anderson; N H Russell
Journal:  Br J Haematol       Date:  1997-07       Impact factor: 6.998

7.  Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose.

Authors:  J Sierra; B Storer; J A Hansen; J W Bjerke; P J Martin; E W Petersdorf; F R Appelbaum; E Bryant; T R Chauncey; G Sale; J E Sanders; R Storb; K M Sullivan; C Anasetti
Journal:  Blood       Date:  1997-06-01       Impact factor: 22.113

8.  Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients.

Authors:  U Dührsen; J L Villeval; J Boyd; G Kannourakis; G Morstyn; D Metcalf
Journal:  Blood       Date:  1988-12       Impact factor: 22.113

9.  Engraftment characteristics of peripheral blood stem cells mobilised with cyclophosphamide and the delayed addition of G-CSF.

Authors:  A Haynes; A Hunter; G McQuaker; S Anderson; N Bienz; N H Russell
Journal:  Bone Marrow Transplant       Date:  1995-09       Impact factor: 5.483

10.  Allogeneic blood stem cell transplantation: considerations for donors.

Authors:  P Anderlini; M Körbling; D Dale; A Gratwohl; N Schmitz; D Stroncek; C Howe; S Leitman; M Horowitz; E Gluckman; S Rowley; D Przepiorka; R Champlin
Journal:  Blood       Date:  1997-08-01       Impact factor: 22.113
View more
  1 in total

1.  Stem cell technology. Interview by Abi Berger.

Authors:  P A Fontes; A W Thomson
Journal:  BMJ       Date:  1999-11-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.